Clinical trial
Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.
NCT06253117 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.
- Lead sponsor
- University of Alabama at Birmingham
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- June 27, 2024
- Completion date
- September 1, 2028
- Enrollment
- 60 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent acute pancreatitis